Heat shock 70 kDa protein 2 (HSPA2) (HSPA2)

Heat shock 70 kDa protein 2 (HSPA2), also referred to as Esophageal cancer-associated oncoprotein 1 (ECAO1), is a molecular chaperone belonging to the heat shock protein 70 (HSP70) family (UniProt: P54652). Originally identified for its critical role in male germ cell development and spermatogenesis, HSPA2 is aberrantly expressed in several human cancers, most notably esophageal squamous cell carcinoma (ESCC) (PMID: 15161543). In these malignancies, HSPA2 acts as an oncoprotein by promoting cell proliferation, migration, and survival while suppressing apoptosis through the stabilization of various signaling proteins and the inhibition of caspase activation (PMID: 15525467). Its high expression levels in tumor tissues are often associated with advanced clinical stages, lymph node metastasis, and poor patient outcomes, making it a significant biomarker for disease progression and prognosis (PMID: 24631433). Therapeutic strategies targeting HSPA2 involve small-molecule inhibitors, such as VER-155008 and Pifithrin-mu, which disrupt its ATPase-dependent chaperone function or substrate-binding capacity (PubChem CID: 9805501). By inhibiting HSPA2, these agents trigger the degradation of essential oncogenic client proteins and induce proteotoxic stress, ultimately leading to tumor cell death. Despite its potential, therapeutic challenges include achieving selectivity over other closely related HSP70 isoforms and managing potential impacts on normal physiological processes like spermatogenesis.

Other names

Esophageal cancer-associated oncoprotein 1ECAO1HSP70-2Heat shock 70kDa protein 2HSPA2

Inhibition of the ATPase activity or substrate binding of the HSPA2 chaperone, leading to the degradation of oncogenic client proteins and induction of apoptosis.